Bacopa Enlighten


Bacopa Enlighten


Ayurvedic Support for Healthy Mental Function

  • A powerful plant extract for improving mental function

  • Helps improve memory and focus

  • Protects the nervous system and boosts antioxidant defenses in the brain

  • Clinically researched and used for centuries to support brain and nervous system function

Buy Online
Use this product for: Brain Health Cellular Health


Bacopa Enlighten is a standardized extract of Bacopa monnieri, an herb used in traditional Ayurvedic medicine to support cognitive function and memory. In India, bacopa is often given to babies in the hopes that it will open the gateway to intelligence.

Bacopa has traditionally been used for improving cognitive functions such as those needed for math and memory skills, for decreasing angst and for reducing mental fatigue at work. It improves the processing of visual information to help increase the rate of learning, lower the rate of forgetfulness, and improve the ability to consolidate new information. Bacopa has also been studied in children with and without ADHD, and benefits have been shown in memory and learning in both scenarios. 

Research has also shown promise for several key concerns of the aging brain.  Animal studies have shown that Bacopa prevents drug induced memory loss and increases protein synthesis in the brain as well as the production of key neural antioxidant enzymes, protecting brain cells from oxidative damage. Young or old, those who want to preserve healthy brain function and memory performance can benefit from Bacopa Enlighten.

Label Info


Bacopa Enlighten contains Bacopa monnieri, an herb used for the support of cognitive function.

Product Variation

Product Code NPN Size
AOR04025 80009764 60 VEGI-CAPS

Supplements Facts

Serving Size: 1 capsule Amount
Bacopa monnieri [Brahmi] extract † (30:1, 50% bacosides A&B) 300 mg

†Equivalent to 9000 mg Bacopa monnieri Linn (whole plant).

Non-medical ingredients:

microcrystalline cellulose, silicon dioxide, sodium stearyl fumarate. Capsule: hypromellose.


AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Adult Dosage

Take 1 capsule daily with/without food, or as directed by a qualified health care practitioner. 


Consult a health care practitioner for use beyond 3 months. May cause nausea, dry mouth and fatigue. Do not use if pregnant or breastfeeding.


Bacopa monnieri extract

Main Application

Cognitive support





The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.



An Ancient Tradition

Bacopa monniera Linn (formerly Herpestis monniera), or water hyssop, is a creeping annual plant with succulent leaves and delicate mauve flowers. While it can be found throughout the world in marshy areas, Bacopa is revered in India, where it is known as Brahmi. The observation that this beautiful botanical supports cognitive function and promotes tranquility goes back to the very beginnings of Ayurveda, the traditional medical system of India. The two core Vedic medical texts, the Caraka Samhita (first to sixth centuries CE) and the Sushruta Samhita, which may go back into the early centuries BCE, both speak of its ability to provide a wide range of benefits to mental function. The later Bhavprakasa Varg-Prakarana informed readers that Brahmi “acts as a brain tonic and promotes longevity.”

Even today, newborn babies in India are ceremonially anointed with Bacopa in the belief that it will open the gateway of intelligence, and children are given Bacopa teas and syrups to promote their mental development.

Bolstering brain function and relieving worry while gearing up the brain’s ability to defend itself from free radical assault, Bacopa forges new steel from the carbon of ancient wisdom and the iron of today’s neuroscience.



Cognitive Function in Children

It is not surprising that most of the earlier human Bacopa trials were performed in children. In one double-blind, placebo controlled study, 110 boys aged 10 to 13 of average intelligence (as measured on IQ tests) took either a Bacopa supplement or a dummy wafer every day for 9 months. Before and after starting the supplement program, the boys took a battery of tests for brain function, including intelligence, memory, and reaction time.  At the end of the trial, there were no significant improvements in the cognitive functioning of the boys who had been given the dummy wafers. But math skills, direct memories, and several subtests of a variation on the IQ tests were all significantly improved in the boys who took the Bacopa supplement.

Stress, Productivity & Blood Pressure Stabilization

Studies have now also been performed in adults. One of them focused on people with worry – another aspect of cognitive function for which Bacopa is traditionally believed to be helpful. After four weeks of taking a Bacopa syrup, a group of 35 workers considered worriers were found to have improved memory, less stress, better social adjustment (as measured by the Asthana-Bell adjustment inventory), and less mental fatigue at work – something measurable in terms of greater work output. The supplement also helped to regulate their blood pressure.

Good Things Take Time

All of these effects were mild, however – probably because of the short duration of the trial. A longer (twelve-week), better-designed study on the brain-boosting powers of Bacopa has given the herb a much stronger endorsement. Australian researchers performed a double-blind, placebo-controlled study involving 46 healthy men and women. The whole group took a battery of neuropsychological tests. Then, half of this group took 300 mg daily of a Bacopa supplement (carefully standardized to contain at least 50% of the two known active markers, bacosides A and B) while the other half took a placebo.

The participants were re-tested five weeks later, and again at the twelve week mark. No significant differences between the folks taking the real supplement and those taking the bogus pill were reported after the first five weeks – a fact which might explain why the effects in the four-week syrup study, discussed above, were so mild. But at the end of the twelve-week study, compared to the group taking the placebo pill, men and women supplementing with Bacopa showed significant improvements in cognitive function, processing visual information 15% faster as measured by the inspection time (IT) test, showing a 14% greater rate of learning, a 33% lower rate of forgetting, verbal information, along with a remarkable 108% better ability to consolidate new information without interference from previously-learned data (“proactive interference”) – all detected by Rey’s Auditory Verbal Learning Test (AVLT), still the standard for verbal learning tests.

Safe and Sound

Few side effects were seen in the study, the most notable being an increase in thirst and urination. And, interestingly, the people taking Bacopa actually suffered fewer headaches than did those getting the dummy pills!

Neuroprotective Effects in Animals

Recent animal studies have given us some exciting clues about the potential neuroprotective effects of this Ayurvedic secret. Bacopa has been shown to protect animals from drug-induced memory losses and the depletion of the key memory neurotransmitter acetylcholine in the hippocampus – the seahorse-shaped organ of the brain responsible for sorting new information for storage into memory. It has also been found to increase the synthesis of new protein in the rodent brain. But the most exciting of the recent animal studies shows that Bacopa boosts the brain’s production of the key protective antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT). In this, Bacopa is closely paralleling the effects of deprenyl (selegiline), a drug prescribed for Parkinson’s disease, which is also being taken by many people in the life extension movement because animal studies suggest that it has potent anti-aging effect. Remarkably, however, the effects of Bacopa were shown to be even broader ranging than those of deprenyl: Bacopa cranked up levels of these enzymes in every tested area of the brain, while deprenyl failed to upregulate these enzymes in the hippocampus.


Market Trends

Natural ways to protect improve the function of the brain is a common concern. Some of the natural ingredients that people are using to improve brain function include antioxidants, botanicals and herbal supplements. Bacopa is to Ayurveda what Ginkgo is to the North American market for brain health, except without the blood thinning and microcirculation effects.

AOR Advantage

Bacopa Enlighten is an extract of a traditional Ayurvedic plant that has been safely used for centuries to support the function of the brain. It has powerful protective effects on the brain and nervous system and has been found in clinical studies to boost mental function.


Abhang R. “Study to evaluate the effect of a micro (suksma) medicine derived from Brahmi (Herpestris monniera) on students of average intelligence.” J Res Ayurved Siddha. 1993; 14(1-2): 10-24.

Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. “Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus.” Phytother Res. 2000 May; 14(3): 174-9.

Bhattacharya SK, Kumar A, Ghosal S. “Effect of Bacopa monniera on animal models of Alzheimer’s disease and perturbed central cholinergic markers of cognition in rats.” In Mori A, Satoh T (eds). Emerging Drugs. Vol 1: Molecular Aspects of Asian Medicines. 2001;Westbury, NY: PJD Publications, 21-32.

Dave UP, Dingankar SR, Saxena VS, Joseph JA, Bethapudi B, Agarwal A, Kudiganti V. An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children. Adv Mind Body Med. 2014 Spring;28(2):10-5.

Negi KS, Singh YD, Kushwaha KP, Rastogi CK, Rathi AK, Srivastava JS, Asthana OP, Gupta RC, Lucknow G. “Clinical evaluation of memory enhancing properties of Memory Plus in children with Attention Deficit Hyperactivity Disorder.” Indian Journal of Psychiatry, 2000 Apr; 42(2) Supplement

Singh RH, Singh L. “Studies on the anti-anxiety effect of the medyha rasayana drug, Brahmi (Bacopa monniera Wettst).” Part I. J Res Ayurved Siddha. 1980; 1:133-48.

Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ. “The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects.” Psychopharmacology (Berl). 2001 Aug; 156(4): 481-4.



An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children.

Adv Mind Body Med. 2014 Spring;28(2):10-5.

Dave UP, Dingankar SR, Saxena VS, Joseph JA, Bethapudi B, Agarwal A, Kudiganti V.

CONTEXT: Attention-deficit hyperactivity disorder (ADHD) is a clinically heterogeneous disorder of inattention, hyperactivity, and impulsivity or difficulty in controlling behavior. Psychostimulant medications remain the mainline treatment for children with ADHD; however, the average response rate to these medications is 70%, and up to 30% of children do not respond to these medications or are unable to tolerate such potential adverse effects as nausea, insomnia, and weight loss.

OBJECTIVE: The study investigated the effectiveness of standardized Bacopa monnieri extract (SBME) in ameliorating the severity of the symptoms of ADHD in children.

DESIGN: The clinical trial was conducted as an open-label study.

SETTING: The study was conducted at the Center for Research in Mental Retardation (CREMERE) in Mumbai, India, from 2008 to 2010.

PARTICIPANTS: Thirty-one children were participants in the trial. They were 6-12 y of age, with an age of onset of ADHD before 7 y of age, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for ADHD.

INTERVENTION: The children received SBME at a dose of 225 mg/d for a period of 6 mo. The specific SBME used in the study was BacoMind (M/s Natural Remedies, Bangalore, India).

OUTCOME MEASURES: Subsequent to the screening of participants, the research team administered the Parent Rating Scale to assess the ADHD symptom scores at baseline, and the team administered it again at the end of the 6 mo of treatment.

RESULTS: SBME significantly reduced the subtests scores of ADHD symptoms, except for social problems. The symptom scores for restlessness were reduced in 93% of children, whereas improvement in self-control was observed in 89% of the children. The attention-deficit symptoms were reduced in 85% of children. Similarly, symptom scores for learning problems, impulsivity, and psychiatric problems were reduced for 78%, 67%, and 52% of children, respectively. It was observed that 74% of the children exhibited up to a 20% reduction, while 26% of children showed between a 21% and a 50% reduction in the total subtests scores.

CONCLUSION: Standardized extract of B monnieri was found to be effective in alleviating the symptoms of ADHD and was well-tolerated by the children.


Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain.

Neurotoxicology. 2006 Jul;27(4):451-7.

Jyoti A, Sharma D.

Bacopa monniera is a nerve tonic used extensively in traditional Indian medicinal system “Ayurveda”. Reports regarding its various antioxidative, adaptogenic and memory enhancing roles have already appeared in the last few decades. In the present study, aluminium chloride (AlCl(3)) was used to generate neurotoxicity. We have investigated the neuroprotective effect of Bacopa extract against aluminium-induced changes in peroxidative products, such as thio-barbituric acid-reactive substance (TBA-RS) and protein carbonyl contents and superoxide dismutase (SOD) activity. Effect on lipofuscin (age pigments) accumulation and ultrastructural changes were also studied. Bacopa effects were compared with those of l-deprenyl. Co-administration of Bacopa extract during aluminium treatment significantly prevented the aluminium-induced decrease in SOD activity as well as the increased oxidative damage to lipids and proteins. Protective effect was also observed at microscopic level. Fluorescence and electron microscopic studies revealed considerable inhibition of intraneuronal lipofuscin accumulation and necrotic alteration in the CA1 region of the hippocampus. Observations showed that Bacopa’s neuroprotective effects were comparable to those of l-deprenyl at both biochemical and microscopic levels.


Cigarette smoking induces heat shock protein 70 kDa expression and apoptosis in rat brain: Modulation by bacoside A.

Neuroscience. 2006;138(4):1127-35.

Anbarasi K, Kathirvel G, Vani G, Jayaraman G, Shyamala Devi CS.

Cigarette smoking is associated with the development of several diseases and antioxidants play a major role in the prevention of smoking-related diseases. Apoptosis is suggested as a possible contributing factor in the pathogenesis of smoking-induced toxicity. Therefore the present study was designed to investigate the influence of chronic cigarette smoke exposure on apoptosis and the modulatory effect of bacoside A (triterpenoid saponin isolated from the plant Bacopa monniera) on smoking-induced apoptosis in rat brain. Adult male albino rats of Wistar strain were exposed to cigarette smoke and simultaneously administered with bacoside A (10 mg/kg b.w./day, orally) for a period of 12 weeks. Expression of brain hsp70 was analyzed by Western blotting. Apoptosis was identified by DNA fragmentation, terminal deoxynucleotidyl transferase-mediated deoxy uridine triphosphate nick end labeling (TUNEL) staining and transmission electron microscopy. The results showed that exposure to cigarette smoke induced hsp70 expression and apoptosis as characterized by DNA laddering, increased TUNEL-positive cells and ultrastructural apoptotic features in the brain. Administration of bacoside A prevented expression of hsp70 and neuronal apoptosis during cigarette smoking. We speculate that apoptosis may be responsible for the smoking-induced brain damage and bacoside A can protect the brain from the toxic effects of cigarette smoking.


Study to evaluate the effect of a micro (suksma) medicine derived from Brahmi (Herpestris monierra) on students of average intelligence.

J Res Ayurved Siddha. 1993; 14(1-2): 10-24.

Abhang R.

A double-blind controlled study was carried out to evaluate the effect of a micro (suksma) medicine derived from Brahmi (Herpestris monniera) by 9 months treatment on 110 boy-students in the age range of 10-13 years and having average IQ (100). Various factors of intelligence were measured before and after treatment. Mean differences in post-testing and pre-testing IQ scores in the experimental group were statistically significant as compared to the control group on the following IQ tests: Memory (Direct) test, Arithmatic test and 4 subtests of Budhimapana test. The result is interesting since in previous studies Ayurvedic medhya rasayanas were not found effective in enhancing intelligence of average students. Long-term studies may prove still more fruitful.


The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects.

Psychopharmacology (Berl) 2001 Aug;156(4):481-4

Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ.

RATIONALE: Extracts of Bacopa monniera have been reported to exert cognitive enhancing effects in animals. However, the effects on human cognition are inconclusive.

OBJECTIVE: The current study examined the chronic effects of an extract of B. monniera (Keenmind) on cognitive function in healthy human subjects.

METHODS: The study was a double-blind placebo-controlled independent-group design in which subjects were randomly allocated to one of two treatment conditions, B. monniera (300 mg) or placebo. Neuropsychological testing was conducted pre-(baseline) and at 5 and 12 weeks post drug administration.

RESULTS: B. monniera significantly improved speed of visual information processing measured by the IT task, learning rate and memory consolidation measured by the AVLT ( P <0.05), and state anxiety (P<0.001) compared to placebo, with maximal effects evident after 12 weeks.

CONCLUSIONS: These findings suggest that B. monniera may improve higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory.


Clinical evaluation of memory enhancing properties of Memory Plus in children with Attention Deficit Hyperactivity Disorder.

Indian Journal of Psychiatry, 2000 Apr; 42(2) Supplement

Negi KS, Singh YD, Kushwaha KP, Rastogi CK, Rathi AK, Srivastava JS, Asthana OP, Gupta RC, Lucknow G.

Memory Plus consists of standardised extract (active constituent identified as Bacosides A & B) from the plant Bacopa monniera, commonly known as Brahmi. Bacosides have undergone extensive pharmacological and toxicity evaluation at Central Drug Research Institute, Lucknow. They facilitate acquisition, consolidation and retention of newly acquired behavioural responses in animal models. The safety and tolerability studies in healthy volunteers have shown them to be safe after single and multiple dose administration. The present study was undertaken to evaluate the memory enhancing properties of Memory Plus in children suffering from Attention Deficit Hyperactivity Disorder (ADHD). In this trial a double blind randomised placebo controlled design was employed. The treatment was assigned to each patient as per random allocation (Memory Plus or placebo). A total of 36 patients were selected as per DSM-IV criteria of ADHD. Of these, 19 patients received Memory Plus (50 mg bd x 12 weeks) and 17 were given placebo. The active drug treatment was followed by a 4 week placebo administration, making the total duration of the trial 16 week in both groups. One patient in the Memory Plus group and 6 in the placebo group dropped out. The mean age was 8.3 years and 9.3 years in Memory Plus and placebo group respectively. The male to female ratio was 5 : 1 in Memory Plus group and 3 : 1 in placebo group. The children were evaluated on a battery of tests (personal information, mental control, sentence repetition, logical memory, word recall (meaningful), digit span test, world recall (non-meaningful), delayed response learning, picture recall and paired associate learning) before (0-day), during drug administration ( 4, 8 and 12 weeks) and at the end of the study ( 16 weeks). The data analysis has revealed a significant improvement on sentence repetiton, logical memory and paired associate learning following 12 weeks administration of Memory Plus. This improvement was maintained as 16 weeks evaluation conducted after 4 weeks withdrawal of Memory Plus. During the clinical trial Memory Plus has shown excellent tolerability and no drug related adverse effects were reported.


Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus.

Phytother Res 2000 May; 14(3): 174-9

Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S.

The effect of a standardized extract of Bacopa monniera Linn. was assessed on rat brain frontal cortical, striatal and hippocampal superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX) activities, following administration for 7, 14 or 21 days. The effects induced by this extract (bacoside A content 82% /- 0.5%), administered in doses of 5 and 10 mg/kg, orally, were compared with the effects induced by (-) deprenyl (2 mg/kg, p. o.) administered for the same time periods. Bacopa monniera (BM) induced a dose-related increase in SOD, CAT and GPX activities, in all the brain regions investigated, after 14 and 21 days of drug administration. On the contrary, deprenyl induced an increase in SOD, CAT and GPX activities in the frontal cortex and striatum, but not in the hippocampus, after treatment for 14 or 21 days. The results suggest that BM, like deprenyl, exhibits a significant antioxidant effect after subchronic administration which, unlike the latter, extends to the hippocampus as well. The results suggest that the increase in oxidative free radical scavenging activity by BM may explain, at least in part, the cognition- facilitating action of BM, recorded in Ayurvedic texts, and demonstrated experimentally and clinically.


Recommended Products

Ortho Mind

Optimizes Mental Performance

R-Lipoic Acid

The Most Effective Form of Lipoic Acid


Optimize Your Brain Function